12 hrs ago
Sovaldi's Q1 Is A Home Run With Men On Base; Why Gilead May Triple From Here
The company announced an in-line quarter for most of its products, but a monster one for its new product Sovaldi.
Customer Interaction Solutions
Research and Markets: Global HIV Therapeutics in Major Developed Markets to 2019
Thanks to patent expirations of several key therapies, the Human Immunodeficiency Virus treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a Compound Annual Growth Rate of 1.9%.
Reevaluating Gilead Sciences After The Sell-Off
Background : On April 7, Seeking Alpha published an article I wrote on Gilead Sciences .
HIV & AIDS Information :: Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment
Investigators in the United States have developed a risk score to predict which people living with HIV have the highest risk of developing chronic kidney disease.
BMSa s Attachment Inhibitor Shows Promise
A promising trial of Bristol-Myers Squibb's investigational attachment inhibitor GS-663068 raises hope of the introduction of a new antiretroviral drug class, which would especially benefit those with multidrug resistance, aidsmap reports.